Phase II Multicenter Open-Label Trial Evaluating Efficacy and Safety of Nal-IRI in HER2-Negative Breast Cancer with CNS Metastases Progression
- Trial ID
- 2024-514999-41-00
- Protocol
- MEDOPP107
Register record, history and transparency: CTIS.eu
Trial statistics
Diseases & Conditions
Objectives
The primary objective of this multicenter, open-label, phase II trial is to evaluate the **efficacy** of nal-IRI, specifically defined as the intracranial (IC) objective response rate (ORR), in patients with HER2-negative metastatic breast cancer who exhibit documented central nervous system (CNS) progression following whole-brain radiotherapy (WBRT), stereotactic radiosurgery (SRS), and/or surgery. This assessment is conducted according to the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria, with central confirmation using a volumetric parameter. The clinical relevance of this objective lies in its potential to provide a therapeutic option for patients with limited treatment alternatives due to CNS progression.
Secondary objectives include: - Assessing the efficacy of nal-IRI for intracranial (IC), extracranial (EC), and overall lesions, defined by metrics such as ORR, clinical benefit rate (CBR) at 12 weeks, disease control rate (DCR), progression-free survival (PFS), time to response (TTR), duration of response (DoR), maximum tumor shrinkage (MTS), and overall survival, in patients with progressing brain metastases and all patients with CNS involvement. - Evaluating the safety and tolerability of nal-IRI in all patients with CNS involvement. - Assessing the efficacy for overall lesions, using the same metrics, in patients with stable brain metastases.
Participants
The clinical trial involves **participants** diagnosed with **HER2-negative metastatic breast cancer** with nervous system involvement and measurable metastases. The study population includes both female and male patients over the age of 18, with a life expectancy greater than 12 weeks. Participants must have sufficient organ and marrow function, and a diagnosis of metastatic breast cancer. They should have been pretreated with taxanes and have evidence of new or stable brain metastases following previous whole-brain radiotherapy (WBRT), stereotactic radiosurgery (SRS), or surgery. The trial does not involve a vulnerable population. The sponsor has not provided information regarding the total number of participants. Participants are required to have a measurable brain lesion for new and progressive metastases or at least one extracerebral lesion for stable brain metastases. Both genders are included, and participants of childbearing potential must agree to use effective contraception. The selection criteria ensure that participants have a documented central nervous system progression and meet specific health parameters, including an Eastern Cooperative Oncology Group (ECOG) performance status of less than 2. The trial population was selected based on these criteria to assess the efficacy of nal-IRI in this specific patient group.
Plans and Procedures
The clinical trial is a multicenter, open-label, phase II study designed to evaluate the efficacy and safety of **nal-IRI** in patients with HER2-negative metastatic breast cancer with nervous system involvement and measurable metastases. The trial employs a single-arm, prospective design and is not categorized as low intervention. The primary objective is to assess the intracranial objective response rate (ORR) using the modified Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria, with central confirmation by a volumetric parameter. Secondary endpoints include overall response rate (ORR), clinical benefit rate (CBR), disease control rate (DCR), progression-free survival (PFS), time to response (TTR), duration of response (DoR), maximum tumor shrinkage (MTS), and overall survival (OS), all determined using RECIST criteria v.1.1 and RANO-BM criteria.
The trial is expected to run from March 31, 2017, to July 1, 2025. Participants will be involved in the study for a maximum treatment period of 30 days, with the possibility of early termination if they experience disease progression, unacceptable toxicity, or withdrawal of consent. The study includes several key visits: an initial screening visit to confirm eligibility, regular follow-up visits to monitor response and safety, and an end-of-study visit to assess final outcomes. Inclusion criteria require participants to be over 18 years of age, have a life expectancy of more than 12 weeks, and meet specific organ and marrow function parameters. Exclusion criteria are not explicitly detailed in the provided data.
Participants will receive **irinotecan** in the form of Onivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion, administered intravenously. The maximum daily dose is 50 mg/m², with a total dose not exceeding 750 mg/m². The study aims to provide comprehensive data on the efficacy and safety of nal-IRI in this patient population, with results contributing to the understanding of treatment options for HER2-negative metastatic breast cancer with central nervous system involvement.
Treatment
The clinical trial involves the administration of **Onivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion**, which contains the active substance **irinotecan**. This experimental medication is provided in the form of a concentrate for dispersion, specifically designed for intravenous infusion. The dosing regimen for this trial specifies a maximum daily dose of 50 mg/m², with a total maximum dose not exceeding 750 mg/m² over a treatment period of 30 days. The administration of the drug is conducted intravenously, ensuring direct delivery into the bloodstream for optimal therapeutic effect. The pharmaceutical formulation is not a pediatric formulation and is classified as a chemical product. The product is manufactured by Les Laboratoires Servier (Suresnes) and holds the marketing authorization number EU/1/16/1130/001.
In this study, no non-experimental treatments such as standard-of-care therapy, placebo, or comparator treatments are specified. The focus remains solely on evaluating the efficacy and safety of the experimental medication, Onivyde, in patients with HER2-negative metastatic breast cancer with documented central nervous system progression. Participant compliance with the dosing schedule is monitored throughout the trial to ensure adherence to the protocol and to accurately assess the therapeutic outcomes. The trial aims to determine the intracranial objective response rate as per the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria, with central confirmation by a volumetric parameter.
Efficacy
The efficacy of the investigational product, nal-IRI, in the clinical trial will be assessed primarily through the **intracranial (IC) objective response rate (ORR)**. This will be determined using the modified Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) criteria, with central confirmation by a volumetric parameter. The primary endpoint involves evaluating the complete response (CR) and partial response (PR) in patients with progressive brain metastases. A CR is defined as the disappearance of all CNS target lesions, no new lesions, no corticosteroids, and stable or improved clinical status. A PR is characterized by a decrease of at least 30% in the sum of the longest diameter of CNS target lesions, no new lesions, no corticosteroids, and stable or improved clinical status. Both CR and PR must be sustained for at least four weeks or confirmed centrally according to a volumetric parameter, which requires a 65% volumetric reduction of CNS lesions.
Secondary endpoints include several measures: the ORR defined by a volumetric parameter and RECIST 1.1 criteria, clinical benefit rate (CBR), disease control rate (DCR), progression-free survival (PFS), time to response (TTR), duration of response (DoR), maximum tumor shrinkage (MTS), and overall survival (OS). These will be determined locally by the investigator using RANO-BM criteria for IC lesions and RECIST criteria v.1.1 for IC, extracerebral (EC), and overall lesions. The trial will also monitor patient safety and adverse events (AEs) using the CTCAE v4. The assessments will be conducted in patients with progressing brain metastases and those with CNS involvement, ensuring a comprehensive evaluation of the treatment's efficacy.
Inclusion and Exclusion Criteria
Inclusion Criteria
- Female or male patients > 18 years
- Patients must have sufficient organ and marrow function as defined below: a. Hematopoietic parameters: i. Absolute neutrophil count (ANC) ≥ 1,5 x 109 /L ii. Platelets ≥ 100 x 109 /L iii. Haemoglobin ≥ 9 mg/dL b. Hepatic parameters: i. Total bilirubin ≤ 1.5 mg/dL ii. AST (SGOT)/ALT (SGPT) ≤ 2.5 X institutional upper limit of normal c. Renal parameters: i. Creatinine ≤ 1.5 X institutional upper limits of normal, OR ii. Creatinine clearance ≥ 60 mL/min/1.73 m2 for pts w/ creatinine levels > institutional normal.
- Patients must have a diagnosis of metastatic breast cancer.
- Patients should have been pretreated with taxanes at any time prior to the study enrolment if not formally contraindicated.
- At least one prior chemotherapy regimen for advanced disease.
- Evidence of new brain metastases and/or stable or progressive brain metastases following previous WBRT and/or SRS and/or surgery.
- At least one brain lesion needed to be measurable for new and progressive metastases (≥10 mm on T1-weighted, gadolinium-enhanced magnetic resonance imaging). For stable brain metastases at least one extracerebral lesion need to be measurable.
- HER2 negative breast cancer defined as 0 - 1+ by immunohistochemistry or FISH negative result.
- ECOG performance status <2.
- Life expectancy >12 weeks.
- Participants of childbearing potential must agree to use at least efficient contraception method (even though it is recommendable for them to use a highly effective method) prior to study entry and for the duration of study participation as well as a negative serum pregnancy test within 7 days of study enrolment and at the end of treatment visit.
- Ability to understand and the willingness to sign a written informed consent.
Exclusion Criteria
- Patients must not have previously received nal-IRI or any other form of irinotecan, conventional or liposomal.
- Pregnant or lactating women.
- Patients who have received prior anti-cancer treatment with chemotherapy, endocrine therapy, immunotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin-C) prior to starting study treatment.
- Radiation therapy encompassing more than 30% of bone marrow.
- Significant chronic gastrointestinal disorder with diarrhea as a major symptom (i.e Crohn’s disease, ulcerative colitis, malabsorption, or grade ≥ 2 diarrhea of any etiology at baseline)
- Have a serious concomitant systemic disorder (e.g. active infection including HIV, or cardiac disease) incompatible with the study (at the discretion of investigator), previous history of bleeding diathesis, or treatment with Sintrom or any anti-vitamin K.
- Patients who have symptomatic lymphangitis, dyspnoea at rest or meningeal carcinomatosis. (Patients with asymptomatic involvement may be enrolled in the study.)
- Patients must be recovered from any clinically relevant toxic effects of any prior surgery, radiotherapy or other therapy intended for the treatment of breast cancer. For peripheral neuropathy, up to CTCAE (v4.0) Grade 2 is acceptable for patients with pre-existing condition.
- Patients may not be receiving any other investigational or anticancer agents while on the study.
- History of other malignancies, which could affect compliance with the protocol or interpretation of the results. Patients with malignancies diagnosed more than 5 years prior to study day 1, adequately treated carcinoma in situ of the cervix or basal or squamous cell skin are generally eligible.
- NYHA Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure. Or known abnormal ECG with clinically significant abnormal findings.
- Active infection or an unexplained fever >38.5°C (excluding tumoral fever), which in the physician’s opinion might compromise the patient’s health.
- Patients with other significant disease or disorders that, in the Investigator's opinion, would exclude the patient from the study.
- Current use or any use in the last two weeks of strong CYP3A-enzyme inducers/inhibitors and/or strong UGT1A inhibitors
- Known hypersensitivity to any of the components of nanoliposomal irinotecan (nal-IRI), other liposomal irinotecan formulations or irinotecan.
Trial Status by Country
| Country | Status | Start of Recruitment | Planned Patients |
|---|---|---|---|
Spain | Not Recruiting | 31 Mar 2017 | 56 |
Sites & Investigators
Investigational Products
Details about the medicinal products being studied in this clinical trial.
| Product Name | Role in Trial | Formulation | Administration | Max Daily Dose | Treatment Duration | EU MP Number |
|---|---|---|---|---|---|---|
Onivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion | Test | CONCENTRATE FOR DISPERSION FOR INFUSION | INTRAVENOUS | 50 | 30 | PRD6811022 |

